189. Back to Basics - Extensive Stage Small Cell Lung Cancer
About this episode
The episode explores extensive stage small cell lung cancer and discusses new treatments and clinical trial results.
This week, we return to our regular programming with a back-to-basics exploration of extensive small-cell lung cancer. A notorious killer and an aggressive type of lung cancer, it has seen new treatments developed at a faster rate than in the last twenty years combined. We explore tarlatamab, a bispecific delta-like ligand 3-directed T cell engager. The results show that, in the second-line setting, it improves overall survival (spoiler alert). The second study is IMforte, utilising lurbinectedin plus atezolizumab in the first-line setting for extensive-stage SCLCa. Again, a positive trial showing an improved median overall survival of 13.2 months vs 10.6 months, but does the toxicity profile trade off support this modest OS benefit? Tune in to find out! Studies discussed in this episode: Imforte DeLLphi-304 For more episodes, resources and blog posts, visit www.inquisitiveonc.com Please find us on Twitter @InquisitiveOnc! If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com Art courtesy of Taryn Silver Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/ Disclaimer: This podcast is for educational purposes only. If…
Sponsors
Pfizer, Gilead Pharmaceuticals, Merck Pharmaceuticals
More episodes of Oncology for the Inquisitive Mind
- 198. Back to Basics - Early Oesophageal Cancer
- 197. Back to Basics - Metastatic Colorectal Cancer - HER2 positive disease and PI3K mutations
- 196. Back to Basics - Metastatic Colorectal Cancer - BRAFV600E and KRAS
- 195. Back to Basics - Immunotherapy in Metastatic Colorectal Cancer
- 194. Back to Basics - Metastatic Colorectal Cancer
- 193. Genitourinary Cancers and Prof Jonathan E Rosenberg MD
Explore listener stats, chart rankings, contacts and more on the Oncology for the Inquisitive Mind podcast page.